Abstract
A deletion variant in the CHEK2 gene (del1100C) has been implicated as a low-penetrance risk factor for breast cancer. We sought to determine contribution of CHEK2 mutations to the etiology of ovarian cancer (OvCa). We used cases ascertained from the United States through Gynecologic Oncology Group (GOG) protocols 172, 182, and 144, the University of Hawaii Cancer Research Center, and Creighton University. Control women were recruited from Pittsburgh and Hawaii. Denaturing high-performance liquid chromatography, sequence analysis, and single nucleotide polymorphism genotyping by Pyrosequencing were employed to analyze the CHEK2 gene. Mutation screening of the CHEK2 gene in 48 cases who had a first-degree relative with OvCa uncovered only del1100C and A252G variants. Altogether, the del1100C variant was detected in none of 751 unselected cases, in 1 of 52 (1.9%) cases who had a first-degree relative with OvCa, and in 3 of 521 (0.6%) unselected controls. The frequencies of del1100C and A252G variants did not show statistically significant differences between the cases and the controls. These results suggest that variations in CHEK2 do not make a significant contribution to the pathogenesis of OvCa in the U.S. population.
| Original language | English |
|---|---|
| Pages (from-to) | 62-69 |
| Number of pages | 8 |
| Journal | Gynecologic Oncology |
| Volume | 95 |
| Issue number | 1 |
| DOIs | |
| State | Published - Oct 2004 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Obstetrics and Gynecology
- Oncology
Cite this
Analysis of CHEK2 gene for ovarian cancer susceptibility. / Baysal, Bora E.; DeLoia, Julie A.; Willett-Brozick, Joan E.; Goodman, Marc T.; Brady, Mark F.; Modugno, Francesmary; Lynch, Henry T.; Conley, Yvette P.; Watson, Patrice; Gallion, Holly H.
In: Gynecologic Oncology, Vol. 95, No. 1, 10.2004, p. 62-69.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Analysis of CHEK2 gene for ovarian cancer susceptibility
AU - Baysal, Bora E.
AU - DeLoia, Julie A.
AU - Willett-Brozick, Joan E.
AU - Goodman, Marc T.
AU - Brady, Mark F.
AU - Modugno, Francesmary
AU - Lynch, Henry T.
AU - Conley, Yvette P.
AU - Watson, Patrice
AU - Gallion, Holly H.
PY - 2004/10
Y1 - 2004/10
N2 - A deletion variant in the CHEK2 gene (del1100C) has been implicated as a low-penetrance risk factor for breast cancer. We sought to determine contribution of CHEK2 mutations to the etiology of ovarian cancer (OvCa). We used cases ascertained from the United States through Gynecologic Oncology Group (GOG) protocols 172, 182, and 144, the University of Hawaii Cancer Research Center, and Creighton University. Control women were recruited from Pittsburgh and Hawaii. Denaturing high-performance liquid chromatography, sequence analysis, and single nucleotide polymorphism genotyping by Pyrosequencing were employed to analyze the CHEK2 gene. Mutation screening of the CHEK2 gene in 48 cases who had a first-degree relative with OvCa uncovered only del1100C and A252G variants. Altogether, the del1100C variant was detected in none of 751 unselected cases, in 1 of 52 (1.9%) cases who had a first-degree relative with OvCa, and in 3 of 521 (0.6%) unselected controls. The frequencies of del1100C and A252G variants did not show statistically significant differences between the cases and the controls. These results suggest that variations in CHEK2 do not make a significant contribution to the pathogenesis of OvCa in the U.S. population.
AB - A deletion variant in the CHEK2 gene (del1100C) has been implicated as a low-penetrance risk factor for breast cancer. We sought to determine contribution of CHEK2 mutations to the etiology of ovarian cancer (OvCa). We used cases ascertained from the United States through Gynecologic Oncology Group (GOG) protocols 172, 182, and 144, the University of Hawaii Cancer Research Center, and Creighton University. Control women were recruited from Pittsburgh and Hawaii. Denaturing high-performance liquid chromatography, sequence analysis, and single nucleotide polymorphism genotyping by Pyrosequencing were employed to analyze the CHEK2 gene. Mutation screening of the CHEK2 gene in 48 cases who had a first-degree relative with OvCa uncovered only del1100C and A252G variants. Altogether, the del1100C variant was detected in none of 751 unselected cases, in 1 of 52 (1.9%) cases who had a first-degree relative with OvCa, and in 3 of 521 (0.6%) unselected controls. The frequencies of del1100C and A252G variants did not show statistically significant differences between the cases and the controls. These results suggest that variations in CHEK2 do not make a significant contribution to the pathogenesis of OvCa in the U.S. population.
UR - http://www.scopus.com/inward/record.url?scp=4644273978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644273978&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2004.07.015
DO - 10.1016/j.ygyno.2004.07.015
M3 - Article
VL - 95
SP - 62
EP - 69
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 1
ER -